Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | SCD | O00767 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.53 |
| ▸ | TOP1 | P11387 | 2/20 | 0.50 |
| ▸ | GCK | P35557 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12021408 | 0.86 | GCK (0.52) | GCK | |
| SCHEMBL16674415 | 0.86 | GCK (0.49) | MEN1KMT2AGCKKDM4EL3MBTL1 | |
| SCHEMBL12021481 | 0.85 | GCK (0.55) | NPC1RAB9AGCKSMN1; SMN2 | |
| SCHEMBL18707629 | 0.84 | GCK (0.62) | NPC1RAB9AMEN1KMT2AGCK | |
| SCHEMBL12021499 | 0.84 | GCK (0.62) | NPC1RAB9AMEN1KMT2AGCK | |
| SCHEMBL12021355 | 0.82 | GCK (0.52) | GCK | |
| SCHEMBL12021520 | 0.81 | GCK (0.52) | NPC1RAB9AMEN1KMT2AGCK | |
| SCHEMBL12021541 | 0.81 | GCK (0.51) | GCK | |
| SCHEMBL12021296 | 0.80 | GCK (0.52) | NPC1RAB9AMEN1KMT2AGCK | |
| SCHEMBL12021247 | 0.80 | GCK (0.75) | NPC1RAB9AGCKSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174062-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10005805-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-10005805-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9522926-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522926-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-30 | — | — | US | disclosed |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-30 | — | — | US | disclosed |
| US-8940927-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940927-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20110294758-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110294758-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005805-B2 | — | GCKR, GCK, HK1 | NPC1 751/4885SCD 651/4885RAB9A 2395/4885 |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | NPC1 1223/4885SCD 921/4885RAB9A 2391/4885 |
| US-20110294758-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | NPC1 1223/4885SCD 921/4885RAB9A 2391/4885 |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | NPC1 1223/4885SCD 921/4885RAB9A 2391/4885 |
| US-10174062-B2 | Activators of glucokinase | GCKR, GCK, HK1 | NPC1 1265/4885SCD 894/4885RAB9A 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.